Objectives: To evaluate high-dose barbiturates as a second-tier therapy for pediatric refractory intracranial hypertension complicating severe traumatic brain injury. Design: This is a ...

There is significant risk of complication related to the placement of shunts for IIH, including shunt failure, and intracranial hypotension and infection, requiring revision, explantation ...

Objective: To explore the diagnosis of cerebral venous sinus stenosis(CVSS) in idiopathic intracranial hypertension(IIH)，and to evaluate the efficacy and risk of ...

Adequate Sleep Significantly Reduces the Risk of Hypertension in Adolescents Nov. 11, 2024 — Adolescents who meet the recommended guidelines of nine to 11 hours of sleep per day were shown to ...

In patients with high comorbidity burden that receive EVT for MCA medium-vessel occlusion there are worse clinical outcomes.

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

We present a case of unilateral, secondary open-angle glaucoma due to an underlying diffuse iris melanoma. The patient was referred by his ophthalmologist with uncontrolled, elevated intraocular ...

An inquest into the homicide of a grandfather who died at the hands of a dementia patient in an aged care facility has found ...

Thurner syndrome (MTS) is a clinicopathological condition where the left common iliac vein is compressed by the overlying right common iliac artery, potentially leading to deep vein thrombosis (DVT) ...

John Friend, MD, CEO of Kazia Therapeutics added, "The novelty of the science that Professor Rao has proposed with this dual ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...

Merck , known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background ...